A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.

NCT Number	NCT05878769
Lead Sponsor	Hoffmann-La Roche
Conditions	Chronic Obstructive Pulmonary Disease
Enrollment	2,000 participants
Start Date	2023-06-28
Primary Completion	2034-07-01 (estimated)
Study Completion	2034-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-02